Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Climb Bio, Inc. (NASDAQ:CLYM) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.50.

Several equities research analysts recently issued reports on CLYM shares. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of Climb Bio in a research report on Thursday, October 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. William Blair began coverage on Climb Bio in a research report on Thursday, October 16th. They set an “outperform” rating for the company. HC Wainwright boosted their target price on shares of Climb Bio from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Wall Street Zen cut shares of Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday, November 8th.

Insider Activity

In related news, Director Ra Capital Management, L.P. bought 101,462 shares of Climb Bio stock in a transaction dated Friday, December 12th. The stock was acquired at an average cost of $2.86 per share, with a total value of $290,181.32. Following the completion of the acquisition, the director directly owned 3,396,318 shares in the company, valued at approximately $9,713,469.48. This trade represents a 3.08% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 321,672 shares of company stock worth $779,626 over the last quarter. 0.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Climb Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Peapod Lane Capital LLC lifted its stake in Climb Bio by 0.7% in the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after acquiring an additional 4,126 shares in the last quarter. Susquehanna International Group LLP boosted its holdings in shares of Climb Bio by 128.4% during the 3rd quarter. Susquehanna International Group LLP now owns 142,450 shares of the company’s stock worth $286,000 after buying an additional 80,092 shares during the period. Prelude Capital Management LLC acquired a new position in Climb Bio during the 3rd quarter worth $82,000. ADAR1 Capital Management LLC boosted its holdings in Climb Bio by 11.9% during the third quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after acquiring an additional 14,210 shares during the period. Finally, UBS Group AG grew its holdings in Climb Bio by 6.0% in the 3rd quarter. UBS Group AG now owns 405,404 shares of the company’s stock valued at $815,000 after buying an additional 22,922 shares during the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Stock Performance

Shares of CLYM opened at $4.65 on Friday. The company has a market capitalization of $317.06 million, a P/E ratio of -6.12 and a beta of -0.15. The stock has a 50-day moving average price of $3.92 and a 200 day moving average price of $2.64. Climb Bio has a one year low of $1.05 and a one year high of $5.60.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). As a group, equities research analysts forecast that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.